Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men
ConclusionsThe present data suggest that TTh in severely obese, hypogonadal individuals induces metabolically healthier preadipocytes, improving insulin sensitivity, mitochondrial functioning and lipid handling. A potentially protective role for testosterone on the progression of NAFLD, improving hepatic steatosis and reducing intrahepatic triglyceride content, was also envisaged.Clinical Trial RegistrationClinicalTrials.gov Identifier: NCT02248467, September 25th 2014
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Bariatric Surgery | Clinical Trials | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Genetics | Insulin | Liver | Liver Disease | Low Testosterone | Mitochondria | Mitochondrial Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Urology & Nephrology